Print

Egenix, Inc. Announces New Director  
11/6/2012 9:09:14 AM

MILLBROOK, N.Y., Nov. 5, 2012 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc., is pleased to announce the appointment of Rainer Fuchs, Ph.D. to its Board of Directors. Dr. Fuchs is a former V.P. of Biogen Idec and currently Chief Information Officer at Harvard Medical School in Cambridge, Massachusetts. Dr. Fuchs will be a substantial asset to the company. Additionally, the Company has added the following scientist to complete its Drug Development Team: Bob Bishop, Ph.D., Jerry Shipps, Ph.D., Alan Cooper, Ph.D., and Arshad Siddiqui, Ph.D.

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an important cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated by a gene product that is regulated by this translation initiation factor. Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction. For more information visit www.egenixinc.com.

SOURCE Egenix, Inc.


//-->